FDA OKs monoclonal antibody COVID-19 therapy for mild-to-moderate illness



The Food and Drug Administration (FDA) on Wednesday granted emergency use authorization to a monoclonal antibody therapy to treat mild-to-moderate COVID-19 in adults and pediatric patients ages 12 and older who are considered at high risk for progression to severe disease.

By Healthy Tips